A randomized, placebo-controlled clinical trial has demonstrated that Lactobacillus rhamnosus SP1—a specific bacterial strain—can reduce inflammatory acne lesions by 32% compared to placebo. In this 12-week study published in Beneficial Microbes, patients who received the probiotic supplement showed statistically significant improvement (P<0.001), with a nearly 28-fold greater likelihood of physician-rated improvement compared to those receiving placebo.
This finding represents one of the more robustly documented probiotics-for-acne results to date, with measurable changes in both skin condition and gene expression. The research matters because acne remains one of the most common skin conditions affecting adults, and conventional treatments—antibiotics, retinoids, hormonal therapy—don’t work equally well for everyone and can carry side effects. A safe, oral probiotic option backed by controlled clinical data offers an alternative worth examining, particularly for individuals seeking gentler interventions or those who don’t respond adequately to standard dermatological care.
Table of Contents
- How Does L. Rhamnosus SP1 Fight Acne Lesions at the Cellular Level?
- Study Design and Dosage: What Made This Trial Credible?
- The Role of the Gut-Skin Axis in Acne Development
- How L. Rhamnosus SP1 Compares to Other Acne Treatments
- Strain Specificity and Why Not All Probiotics Are Equivalent
- Gene Expression Data: What Does a 65% Increase in IGF1 and FOXO1 Mean?
- Implications and Future Directions for Probiotic Acne Research
- Conclusion
How Does L. Rhamnosus SP1 Fight Acne Lesions at the Cellular Level?
The mechanism behind L. rhamnosus SP1’s effectiveness appears to operate through multiple pathways, including modulation of skin gene expression and immune function. In the trial, patients who received the probiotic showed a 65% increase in expression of the IGF1 and FOXO1 genes in skin tissue—genes associated with cellular repair and inflammatory control—while the placebo group showed no change. The probiotic also improved microbiome diversity and reduced harmful bacteria, both of which contribute to acne formation.
This represents a shift away from older acne theories that blamed bacteria alone; modern research shows that the problem is more about bacterial imbalance and how the immune system responds to microbial shifts. Think of it this way: acne isn’t simply caused by *bad* bacteria, but by a disrupted balance in which opportunistic species like Cutibacterium acnes (formerly called Propionibacterium acnes) overgrow and trigger inflammation. L. rhamnosus SP1 appears to restore equilibrium—reintroducing a beneficial strain that outcompetes harmful ones and simultaneously tells your immune cells to reduce inflammatory signaling. The gene expression data suggests the probiotic doesn’t just fight bacteria; it enhances your skin’s own repair mechanisms.
Study Design and Dosage: What Made This Trial Credible?
The research used a rigorous methodology that distinguishes it from anecdotal claims or poorly controlled studies. Twenty adult volunteers (14 women, 6 men, average age 33.7 years) received either 75 mg daily of L. rhamnosus SP1 (containing 3 billion colony-forming units, or 3×10⁹ CFU) or an identical-looking placebo for 12 weeks in a double-blind format—meaning neither the patients nor the dermatologists assessing results knew who received which treatment. Lesion counts were performed at baseline, week 4, week 8, and week 12.
Blood samples and skin biopsies were collected to measure gene expression changes. The dosage used (75 mg daily, 3 billion CFU) is modest compared to some probiotic supplements on the market, many of which contain 10-50 billion CFU. This is important because it suggests that efficacy didn’t require a megadose. However, a limitation of this trial is its small sample size—20 subjects is enough to establish proof of concept but not enough to determine which patient populations benefit most or whether results hold across different demographics. A more recent 2024 trial with a larger cohort (40 probiotic recipients, 34 placebo) reported that 50% of the probiotic group achieved improvement on standard acne severity scales versus 29.41% of placebo recipients (P=0.03), which independently validates the earlier finding.
The Role of the Gut-Skin Axis in Acne Development
Emerging research over the past decade has highlighted the so-called “gut-skin axis”—the bidirectional communication between digestive health and skin condition. Your gut microbiome influences skin through several pathways: by regulating intestinal permeability, controlling systemic inflammation, producing metabolites that reach the skin, and modulating immune tolerance. Dysbiosis (microbial imbalance) in the gut has been associated with acne in observational studies, though causation remains incompletely understood.
L. rhamnosus strains specifically have been studied for their ability to strengthen intestinal barrier function and reduce lipopolysaccharide (LPS) translocation—a process where bacterial toxins enter the bloodstream and amplify inflammation system-wide. By reinforcing gut health, this probiotic may lower the inflammatory baseline affecting not just acne but also overall skin quality. That said, the trial measured clinical acne outcomes rather than detailed gut microbiome changes, so we don’t have a complete picture of exactly how much of the benefit came from gut effects versus direct skin colonization or systemic immune modulation.
How L. Rhamnosus SP1 Compares to Other Acne Treatments
Most conventional acne treatments target either bacterial growth (antibiotics), sebum production (isotretinoin, hormonal contraceptives), or skin cell turnover (retinoids). L. rhamnosus SP1 works differently—it’s a microbial rebalancing agent with immunomodulatory properties. A 32% reduction in inflammatory lesions is clinically meaningful but modest compared to, say, isotretinoin (which can clear severe acne in most patients) or even some topical retinoids (which typically reduce lesions by 50-70% over 12 weeks). Where the probiotic excels is in tolerability and mechanism: there’s no birth defect risk (like isotretinoin), no antibacterial resistance selection pressure, and no skin irritation from topical application.
The tradeoff is time and certainty. Probiotics work through subtler biological mechanisms, so they may take longer to show results and may not be strong enough for severe acne alone. A reasonable clinical approach might be combining L. rhamnosus SP1 with other gentle interventions—proper cleansing, benzoyl peroxide or azelaic acid for bacteria, and dietary adjustments—rather than viewing it as a monotherapy replacement for conventional care in severe cases. For mild to moderate inflammatory acne, particularly in individuals sensitive to antibiotics or retinoids, a 32% lesion reduction could be quite valuable.
Strain Specificity and Why Not All Probiotics Are Equivalent
A critical point often missed in discussions of “probiotics for acne” is that most probiotic effects are highly strain-specific. The fact that L. rhamnosus SP1 showed benefit doesn’t mean all L. rhamnosus strains will, nor does it mean other Lactobacillus species will be equally effective. Probiotic efficacy depends on the exact strain’s adhesion properties, metabolite production, immune-cell signaling, and genetic profile. A different strain of L.
rhamnosus might show no effect at all. This specificity is both good and bad. On the positive side, it means the scientific evidence for L. rhamnosus SP1 is relevant to products containing *that specific strain*—not generic “Lactobacillus” supplements. On the warning side, many commercial products don’t clearly identify the strains they contain, or they contain multiple strains with minimal individual research. Before purchasing a probiotic for acne, verify that the label specifies “L. rhamnosus SP1” (or another strain with published trial data) rather than just “Lactobacillus complex.” Generic probiotic blends might support general health but shouldn’t be marketed as acne treatments without species-and-strain-specific evidence.
Gene Expression Data: What Does a 65% Increase in IGF1 and FOXO1 Mean?
The trial measured changes in insulin-like growth factor 1 (IGF1) and forkhead box protein O1 (FOXO1) gene expression in skin tissue biopsies. Both genes play roles in cellular metabolism, stress resistance, and longevity signaling. Why would a probiotic upregulate these? The leading hypothesis is that beneficial bacterial metabolites and immune signals from L. rhamnosus SP1 shift skin cells toward a more resilient, less inflamed state.
FOXO1 in particular activates stress-resistance and anti-inflammatory pathways; IGF1 influences cell growth and tissue repair. A concrete example: elevated IGF1 in the gut (not the skin) has been implicated in acne worsening, which might seem contradictory. However, *local* upregulation of IGF1 in the skin microenvironment during repair may support healing of acne lesions and damage. The 65% increase reported was statistically significant (P<0.001) and did not occur in the placebo group, supporting the claim that the probiotic specifically triggered this change. Still, gene expression measures are sometimes considered surrogate endpoints—they're not as directly meaningful as a visible reduction in pimples, though they add mechanistic credibility to the findings.
Implications and Future Directions for Probiotic Acne Research
The L. rhamnosus SP1 trial opens questions about optimal dosing, duration, and patient selection. Would higher doses work better? Does benefit persist after stopping the supplement, or is this a maintenance therapy? Do certain acne subtypes (hormonal, diet-related, stress-triggered) respond better than others? A 2025 meta-analysis examining oral probiotics for acne across multiple randomized trials is beginning to synthesize answers, but individual strain studies remain sparse. Future research should explore combination approaches: What if L.
rhamnosus SP1 were paired with a topical retinoid or azelaic acid? Does it enhance their effects or provide redundant benefit? From a regulatory standpoint, probiotics occupy an uncertain space between food supplements and drugs, which varies by country. In the United States, they’re typically marketed as dietary supplements and don’t undergo the rigorous approval pathway that pharmaceuticals do. This means products claiming to contain L. rhamnosus SP1 may vary in quality and viability. For individuals interested in trying this approach, seeking products from reputable manufacturers that publish stability and viability data, and managing expectations about realistic improvement timelines (12 weeks in the trial), is prudent.
Conclusion
Lactobacillus rhamnosus SP1 has demonstrated a 32% reduction in inflammatory acne lesions in a randomized, placebo-controlled trial—a meaningful and statistically significant effect backed by mechanistic data showing increased expression of skin-health-associated genes. The findings are credible because of the rigorous study design, double-blind methodology, and recent independent replication showing 50% of probiotic recipients achieved improvement versus 29% of placebo recipients. For individuals with mild to moderate acne seeking a gentle, non-antibiotic option, this probiotic warrants consideration. The practical takeaway is to approach L.
rhamnosus SP1 as one tool in an integrated acne management plan rather than as a standalone replacement for conventional treatments. Verify that any supplement you purchase actually contains the SP1 strain (not generic Lactobacillus), use it consistently for at least 8-12 weeks, combine it with sun protection and gentle skincare, and monitor results honestly. If after 3 months you see no meaningful improvement, reassess with a dermatologist rather than continuing indefinitely. For many people, this evidence-based probiotic represents a welcome option in the expanding toolkit for managing acne more naturally.
